Liver disease biotech Galmed files for a $35 million IPO

By Renaissance Capital,

Shutterstock photo

Galmed Pharmaceuticals, a clinical-stage biotech developing therapies for liver diseases and gallstones, filed on Thursday with the SEC to raise up to $35 million in an initial public offering. The Tel Aviv, Israel-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol GLMD. Galmed Pharmaceuticals initially filed confidentially on December 31, 2013. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by